Estudio comparativo de melatonina contra los tratamientos inmunomoduladores (interferón beta y acetato de glatirámero) en un modelo murino de esclerosis múltiple-Reference-Cited by-同舟云学术

Estudio comparativo de melatonina contra los tratamientos inmunomoduladores (interferón beta y acetato de glatirámero) en un modelo murino de esclerosis múltiple

Published:2021-05 Issue:4 Volume:36 Page:262-270
ISSN:0213-4853
Container-title:Neurología
language:es
Short-container-title:Neurología

Author:

Ramos González E.J.,Ramirez Jirano L.J.,García Martínez D.Z.,Ortiz G.G.,Jave Suárez L.F.,Leal Cortes C.A.,Bitzer Quintero O.K.

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference39 articles.

1. Multiple sclerosis: Pathogenesis and treatment;Loma;Curr Neuropharmacol.,2011

2. Pathophysiology of multiple sclerosis;Korn;J Neurol.,2008

3. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS);Constantinescu;Br J Pharmacol.,2011

4. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis;Dillingham;Cell Mol Neurobiol.,2015

5. MS International Federation. Atlas of MS [consultado 26 Ene 2016]. Disponible en: http://www.msif.org/about-us/advocacy/atlas/

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Presence of melatonin in foods of daily consumption: The benefit of this hormone for health;Food Chemistry;2024-11

2. The effects of melatonin supplementation on neurobehavioral outcomes and clinical severity in rodent models of multiple sclerosis; a systematic review and meta-analysis;Inflammopharmacology;2024-01-22

3. Effects of melatonin on the management of multiple sclerosis: A scoping review on animal studies;AIMS Medical Science;2024

4. Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway;Scientific Reports;2022-09-24

5. Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action;Inflammopharmacology;2022-06-05